Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib.

MLA

Mulas, Olga, et al. “Favorable Outcome of Chronic Myeloid Leukemia Co-Expressing E13a2 and E14a2 Transcripts, Treated with Nilotinib.” Hematological Oncology, vol. 38, no. 4, Oct. 2020, pp. 607–10. EBSCOhost, https://doi.org/10.1002/hon.2765.

APA

Mulas, O., Caocci, G., Annunziata, M., Martino, B., Luciano, L., Castagnetti, F., Pregno, P., Galimberti, S., Albano, F., Orlandi, E. M., Sgherza, N., Iurlo, A., Bonifacio, M., Binotto, G., Gozzini, A., Bocchia, M., Abruzzese, E., Fozza, C., Simula, M. P., … La Nasa, G. (2020). Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. Hematological Oncology, 38(4), 607–610. https://doi.org/10.1002/hon.2765

Chicago

Mulas, Olga, Giovanni Caocci, Mario Annunziata, Bruno Martino, Luigiana Luciano, Fausto Castagnetti, Patrizia Pregno, et al. 2020. “Favorable Outcome of Chronic Myeloid Leukemia Co-Expressing E13a2 and E14a2 Transcripts, Treated with Nilotinib.” Hematological Oncology 38 (4): 607–10. doi:10.1002/hon.2765.